{"id":534826,"date":"2021-09-07T08:33:22","date_gmt":"2021-09-07T12:33:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-07T08:33:22","modified_gmt":"2021-09-07T12:33:22","slug":"pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">FLORHAM PARK, N.J., Sept.  07, 2021  (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company\u2019s proprietary Versamune<sup>\u00ae<\/sup> T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.\u00a0<\/p>\n<p align=\"justify\">The presentation\u00a0will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune<sup>\u00ae<\/sup>-TARP) and PDS0103 (Versamune<sup>\u00ae<\/sup>-MUC1) into human clinical trials. The conference is taking place virtually from September 13 &#8211; 15, 2021.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>HC Wainwright 23rd Annual Global Investment Conference:<\/strong><br \/>\n        <br \/>Investors can register for the conference <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iZ5WTCR5jab3RyMhdNjb37a8IuSPHBS-bRRpHF2LIxiSw3o_2N4ElmrkOr82HYJeVL8ELPnzqd5YYZupKEDLsQJhcAO9jcF6vktLbN6ETJgglpcQFREYFRHzMPNz1Qjq\" rel=\"nofollow noopener\" target=\"_blank\"><u>HERE.<\/u><\/a><\/p>\n<p align=\"justify\">The presentation will be available on demand beginning at 7:00 am EDT on Monday, September 13, 2021 within the Investor section of the company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E_bA2I9LDxW7i9pqA-Q140uQRMlXJRA1X1IXI2dEW7caMz2D9TprbK0vOlxpRcMI8kfQgUbln1am3Ku2I2Idl2esKcDUygKMehPBPOyqsLE4IIfIqbzlvPqPgZVvD-b0eNJZcmBdLw8UeWk9zrMPtTsXTjt63UZRifgLSNM6OKcqEJXQotlTNuImIQPu_DKlXsfRcEjoJpX2Ve50aK5YPbiNIs-4kIH_Wn58KJBySPuwohFSA4uc0zWWHSN8yQIp7CQjgylHX56mxvMQDG1i6Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/pdsbiotech.com\/<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About PDS Biotechnology<\/strong><br \/>\n        <br \/>PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company\u2019s proprietary Versamune<sup>\u00ae<\/sup> T-cell activating technology platform. Our Versamune<sup>\u00ae<\/sup>-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune<sup>\u00ae<\/sup> and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company\u2019s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. \u00a0To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8trfkl1Mu50TSikYnPOAgw7odfS-qxrN8dAr-qTcElgBOXZkFV_PGSq_ySyPYAABoalYG1zSRAYdnilS7vyYZzO83bQC4_xjg_3DoGLK0sU=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.pdsbiotech.com<\/u><\/a> or follow us on Twitter at @PDSBiotech.<\/p>\n<p align=\"justify\">\n        <strong>About PDS0101<\/strong><br \/>\n        <br \/>PDS Biotech\u2019s lead candidate, PDS0101, combines the utility of the Versamune<sup>\u00ae<\/sup> platform with targeted antigens in HPV-expressing cancers. In partnership with Merck &amp; Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA<sup>\u00ae<\/sup> in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.<\/p>\n<p align=\"justify\">\n        <strong>Media &amp; Investor Relations Contact:<\/strong><br \/>\n        <br \/>Deanne Randolph<br \/>PDS Biotech<br \/>Phone: +1 (908) 517-3613<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TwXQFPbuj6eQtlsZdL2gWmNQR0DZAZDkcsrGaCjYhdrMAtw0wUF73vBnuWwX36PecqJWIHV-FeGLRlvmDgFu-EujqKBYtejAF_bMmpH1UvE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>drandolph@pdsbiotech.com<\/u><\/a><\/p>\n<p align=\"justify\">Rich Cockrell<br \/>CG Capital<br \/>Phone: +1 (404) 736-3838\u00a0<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2nEwkhPet2HusZnMXErRLJyTfxWIFBpR7B_r0FVBigDh2jbX-MWDte-gqNIwxVSpELbq1IwDAAjk2b1_1GYgRw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>rich@cg.capital<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWE0YzhiNTgtZDRjNC00ZjRmLWEwN2ItZTZjYjlmYTFiNWMwLTEwMjg3NjE=\/tiny\/PDS-Biotechnology-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.\u00a0 The presentation\u00a0will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune\u00ae-TARP) and PDS0103 (Versamune\u00ae-MUC1) into human clinical trials. The conference is taking place virtually from September 13 &#8211; 15, 2021.\u00a0 HC Wainwright 23rd Annual Global Investment Conference: Investors can register for the conference HERE. The presentation will be available on demand beginning at 7:00 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534826","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.\u00a0 The presentation\u00a0will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune\u00ae-TARP) and PDS0103 (Versamune\u00ae-MUC1) into human clinical trials. The conference is taking place virtually from September 13 &#8211; 15, 2021.\u00a0 HC Wainwright 23rd Annual Global Investment Conference: Investors can register for the conference HERE. The presentation will be available on demand beginning at 7:00 &hellip; Continue reading &quot;PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T12:33:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-07T12:33:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=\",\"datePublished\":\"2021-09-07T12:33:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company\u2019s proprietary Versamune\u00ae T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.\u00a0 The presentation\u00a0will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune\u00ae-TARP) and PDS0103 (Versamune\u00ae-MUC1) into human clinical trials. The conference is taking place virtually from September 13 &#8211; 15, 2021.\u00a0 HC Wainwright 23rd Annual Global Investment Conference: Investors can register for the conference HERE. The presentation will be available on demand beginning at 7:00 &hellip; Continue reading \"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T12:33:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-07T12:33:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/","name":"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=","datePublished":"2021-09-07T12:33:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDU0MSM0Mzg4OTM4IzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotechnology-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534826"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534826\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}